Progression of romiplostim myelofibrosis to myeloproliferative neoplasm
نویسندگان
چکیده
منابع مشابه
Romiplostim-induced myelofibrosis.
A 55-year-old woman with chronic refractory idiopathic thrombocytopenic purpura (ITP) presented with gum bleeding for 1 day. Over the course of several years, she had failed, or became resistant to, multiple treatments including glucocorticoids, intravenous immunoglobulin, splenectomy, rituximab, and, recently, a 9-month course of weekly romiplostim with moderate compliance. A complete blood co...
متن کاملNon-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
We studied non-driver mutations in 62 subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis upon diagnosis, including 45 subjects with primary myelofibrosis (PMF) and 17 with post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF). Fifty-eight subjects had ≥1 non-driver mutation upon diagnosis. Mutations in mRNA splicing genes, especially in U2A...
متن کاملPtch2 loss drives myeloproliferation and myeloproliferative neoplasm progression
JAK2V617F(+) myeloproliferative neoplasms (MPNs) frequently progress into leukemias, but the factors driving this process are not understood. Here, we find excess Hedgehog (HH) ligand secretion and loss of PTCH2 in myeloproliferative disease, which drives canonical and noncanonical HH-signaling. Interestingly, Ptch2(-/-) mice mimic dual pathway activation and develop a MPN-phenotype with leukoc...
متن کاملCritical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
The recent approval of molecular-targeted therapies for myeloproliferative neoplasm-associated myelofibrosis (MPN-MF) has dramatically changed its therapeutic landscape. Ruxolitinib, a JAK1/JAK2 tyrosine kinase inhibitor, is now widely used for first- and second-line therapy in persons with MPN-MF, especially those with disease-related splenomegaly, intermediate- or high-risk disease, and const...
متن کاملProgression of primary myelofibrosis to polycythemia vera
RATIONALE This case report describes the progression of primary myelofibrosis (PMF) to polycythemia vera (PV), and discuss its potential mechanisms. PATIENT CONCERNS The patient was admitted because of abdominal discomfort and enlarged spleen for 19 months. DIAGNOSIS A case of PMF progressed to PV was retrospectively analyzed. There were 19 months between the diagnosis of PMF and PV. The JA...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2014
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood-2013-09-528778